A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation

Trial Profile

A Phase 3, Two-Arm, Rollover Study to Evaluate the Safety of Long Term Ivacaftor Treatment in Subjects 6 Years of Age and Older With Cystic Fibrosis and a Non-G551D CFTR Mutation

Completed
Phase of Trial: Phase III

Latest Information Update: 17 May 2017

At a glance

  • Drugs Ivacaftor (Primary)
  • Indications Cystic fibrosis
  • Focus Adverse reactions
  • Acronyms KONTINUE
  • Sponsors Vertex Pharmaceuticals
  • Most Recent Events

    • 10 May 2016 Status changed from active, no longer recruiting to completed.
    • 23 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 30 Jun 2014 Interim results published in a Vertex Pharmaceuticals Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top